Medartis Holding AG (XSWX:MED) Research & Development: CHF31.4 Mil (TTM As of Dec. 2025)


XSWX:MED Medartis Holding AG XSWX:MED
76 GF Score
Price CHF72.00
GF Value CHF105.61
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Medartis Holding AG Research & Development?

Medartis Holding AG XSWX:MED -0.55% 76 Research & Development is CHF31.4 Mil as of Dec. 2025. GuruFocus rates XSWX:MED with a GF Score™ of 76/100 and a GF Value™ of CHF105.61 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Medartis Holding AG's Research & Development for the six months ended in Dec. 2025 was CHF17.9 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was CHF31.4 Mil.

Medartis Holding AG  (XSWX:MED) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Medartis Holding AG Research & Development Related Terms

Medartis Holding AG Research & Development Historical Data

* Premium members only.

The historical data trend for Medartis Holding AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medartis Holding AG Research & Development Chart

Medartis Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.05 25.33 25.91 43.10 31.44

Medartis Holding AG Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.50 22.14 20.96 13.58 17.86
XSWX:MED
76GF Score
Medartis Holding AG XSWX:MED
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medartis Holding AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF31.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of CHF31.4 Mil mean?
Medartis Holding AG (XSWX:MED) has a Research & Development of CHF31.4 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Medartis Holding AG and its competitors.
Is Medartis Holding AG's Research & Development too high?
Medartis Holding AG's current Research & Development is CHF31.4 Mil. Overall, Medartis Holding AG has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medartis Holding AG's Research & Development compare to ABT and SYK?
Medartis Holding AG's Research & Development of CHF31.4 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Medartis Holding AG and its competitors. Medartis Holding AG's current Research & Development is CHF31.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medartis Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Medartis Holding AG (XSWX:MED) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF105.61, compared to a current price of CHF72.00 — trading 31.8% below its estimated fair value. The current Research & Development is CHF31.4 Mil. Medartis Holding AG's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Medartis Holding AG (XSWX:MED), the current Research & Development is CHF31.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medartis Holding AG (XSWX:MED) Overvalued in 2026?

Based on GuruFocus' analysis, Medartis Holding AG stock appears to be undervalued. The current stock price of CHF72.00 is trading 31.8% below its estimated GF Value™ of CHF105.61. GuruFocus considers Medartis Holding AG to be Significantly Undervalued.

Key valuation signals for XSWX:MED:

  • Research & Development: CHF31.4 Mil
  • GF Value™: CHF105.61 vs. price of CHF72.00 (31.8% below fair value)
  • GF Score™: 76/100 with 5 warning signs

No single metric tells the full story. See the XSWX:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medartis Holding AG Business Description

Other Exchanges MEDz:UK1RU:Germany
Address Hochbergerstrasse 60E, Basel, CHE, 4057
Medartis Holding AG is a medical device company. The company's product profile is divided into APTUS products, StealthFix Products, and MODUS products. APTUS includes products for the Hand, Wrist, Elbow, Shoulder, and Foot. MODUS comprises products for the mandible. Geographically, it derives the majority of its revenue from Europe, Middle East and Africa (EMEA) and also has a presence in North America, Asia Pacific, and Latin America.
76GF Score

Get the complete analysis for XSWX:MED

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF72.00
Price
CHF105.61
GF Value